Empagliflozin for the Treatment of Postprandial Hypoglycemia
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This randomized trial is to test whether a treatment with empagliflozin is superior to
placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it
improves health related quality of life (mentally or physically) or reduces the risk of
hypoglycemic events.